About this trial
The purpose of this study is to determine the impact of tetrahydrocannabinol (THC) administration on motivational, subjective, and physiological effects of cigarettes. The study's goals are to test demand for cigarettes, tobacco craving, affect, heart rate, blood pressure, expired breath carbon monoxide, and cognitive performance. Researchers will compare multiple doses of THC and a placebo in participants who smoke cigarettes and either smoke or vape THC in the laboratory.
Eligibility criteria
Qualifiers
Healthy non-treatment seeking adults aged 21 or older
Report daily use of combustible tobacco cigarettes
Biological confirmation of cigarette use: have an expired carbon monoxide (CO) level of more than 5 ppm and a positive urine cotinine test at screening
Report current use of cannabis (at least 1 occasion per week)
Disqualifiers
Report current intention to reduce or quit cannabis or tobacco use within the next 30 days
Meet Diagnostic and Statistical Manual (DSM-5) criteria for a substance use disorder other than alcohol, cannabis, or nicotine
Test positive for illicit drugs other than cannabis and tobacco
Positive breath alcohol test at study admission
Trial design
Treatments tested in this trial
- THC 30mg
- THC 5mg
- THC 0mg
- Cigarette Full Nicotine
- Cigarette Reduced Nicotine
Treatment groups
Sponsors and collaborators
Johns Hopkins University
Lead sponsor
National Institute on Drug Abuse (NIDA)
Collaborator